Phospholipase C gamma 2-dependent platelet activation pathway (PLCγ2-TXA2 pathway)

The Phospholipase C gamma 2 (PLCγ2)-dependent signaling pathway is a central biochemical axis in platelet activation and arterial thrombosis. Upon stimulation of receptors such as Glycoprotein VI (GPVI) by collagen, PLCγ2 is activated, leading to the hydrolysis of phosphatidylinositol 4,5-bisphosphate into inositol trisphosphate (IP3) and diacylglycerol (DAG) (UniProt P16885). IP3 triggers the release of intracellular calcium ([Ca2+]), while DAG activates Protein Kinase C (PKC), both of which are essential for platelet shape change and granule secretion (StatPearls, Platelet Activation and Aggregation). This cascade culminates in the activation of cyclooxygenase-1 (COX-1) and the subsequent synthesis of Thromboxane A2 (TXA2), a potent pro-aggregatory lipid mediator (PubChem CID 5280497). Pathological overactivation of this pathway is a major driver of myocardial infarction and ischemic stroke. Therapeutic strategies often target specific components of this pathway, such as aspirin inhibiting TXA2 production or ibrutinib inhibiting upstream Btk-mediated PLCγ2 activation, to manage cardiovascular risk (PubMed: 25633657). Understanding this pathway is critical for developing antiplatelet agents that balance efficacy in preventing thrombosis with the risk of bleeding.

Other names

Coagulation and PLCγ2–IP3/DAG–[Ca2+]–PKC–TXA2 signaling pathwayPLCgamma2-IP3-DAG-Ca2+-PKC-TXA2 axisGPVI-mediated platelet activation signalingPlatelet PLCγ2 signaling cascade

Inhibition of specific enzymatic nodes within the cascade, such as PLCγ2, PKC, or COX-1, to prevent the generation of second messengers and Thromboxane A2, thereby reducing platelet aggregation.